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Glossary 
 
Problem structuring 
 
methods 
A set of formal methods developed within the field of Operational Research 
 
intended to develop consensus, structure and make sense of complex or 
messy problems. 
Conceptual model The abstraction and representation of complex phenomena of interest in 
 
some readily expressible form, such that individual stakeholders’ 
understanding of the parts of the actual system, and the mathematical 
representation of that system, may be shared, questioned, tested and 
ultimately agreed. 
Problem-oriented 
conceptual model 
A form of conceptual model which is developed to understand the decision 
 
problem and the system in which that problem exists. 
Design-oriented 
 
conceptual model 
Conceptual models which are focussed on the consideration of alternative 
 
potentially acceptable and feasible quantitative model designs, to specify the 
model’s evidence requirements and to provide a basis for comparison and 
justification against the final implemented model. 
Disease process 
model 
A problem-oriented conceptual model which sets out the disease-specific 
 
events and processes within the system in which the decision problem exists. 
Service pathways 
 
model 
A problem-oriented conceptual model which sets out the elements of the 
 
service which are relevant to the system in which the decision problem 
exists. 
 
 
Abbreviations 
 
HRQoL Health-related quality of life 
HTA Health Technology Assessment 
NICE National Institute for Health and Clinical Excellence 
PSMs Problem Structuring Methods 
QALY Quality adjusted life year 
SODA Strategic Options Development and Analysis 
SSM Soft Systems Methodology 
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Introduction 
 
Health economic evaluation is a general framework for informing decisions about whether particular 
health technologies represent a cost-effective use of health care resources. Commonly, the evidence 
required to inform a decision about the cost-effectiveness of a given set of competing health 
technologies is not available from a single source. The use of mathematical modelling can be used to 
support this decision-analytic framework thereby allowing the full range of relevant evidence to be 
synthesised and brought to bear on the decision problem.
1 
The process of developing a decision- 
analytic model is generally seen as being iterative, and requires the model developer to make a 
substantial number of choices about what should be included in a model and how these included 
phenomena should be related to one another. These choices take place at every stage of the model 
development process, and include choices about the comparators to be assessed, choices about which 
health states and sequences of events will comprise the model’s structure, choices about which 
evidence  sources  should  be  used  to  inform the  model  parameters,  and  choices  about  statistical 
methods for deriving the model’s parameters, to name but a few. Importantly the absence of perfect 
information through which to comprehensively validate a model means that there is rarely a definitive 
means through which to prospectively determine whether these choices are right or wrong. Instead, 
model development choices are made on the basis of subjective judgements, with the ultimate goal of 
developing a model which will be useful in informing the decision at hand. 
 
 
Therefore, model development is perhaps best characterised as a complex process in which the 
modeller, in conjunction with other stakeholders, determines what is relevant to the decision problem 
(and at the same time, what can reasonably be considered irrelevant to the decision problem). This 
notion of relevance has a direct bearing on the credibility of a model and on the interpretation of 
results generated using that model. Failure to account for the complexities of the decision problem 
may result in the development of models which are “mathematically sophisticated but contextually 
naïve.”2 The development of useful mathematical models therefore requires more than mathematical 
ability alone: it firstly requires the model developer to understand the complexity of the real system 
that the model will attempt to represent, and the choices available for translating this understanding of 
complexity into a credible conceptual and mathematical structure. It is perhaps surprising that whilst 
much has been written about the technical aspects of model development, for example the statistical 
extrapolation of censored data and methods for synthesising evidence from multiple sources, there is a 
comparative dearth of practical guidance surrounding formal processes through which an appropriate 
model structure should be determined. It is this complex and messy subject matter that forms the 
focus of this paper. 
 
 
The purpose of this paper is not to rigidly prescribe how model development decisions should be 
made, nor is it intended to represent a comprehensive guide of “how to model.” The former would 
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undoubtedly fail to reflect the unique characteristics of each individual decision problem and could 
discourage the development of new and innovative modelling methods. Conversely, the latter would 
inevitably fail to reflect the sheer breadth of decisions required during model development. Rather, 
the purposes of this paper are threefold: 
(1) To highlight that structural model development choices invariably exist; 
 
(2) To  suggest  a  generaliseable  and  practical  hierarchical  approach  through  which  these 
alternative choices can be prospectively exposed, considered and assessed, and; 
(3) To highlight key issues and caveats associated with the use of certain types of evidence in 
informing the conceptual basis of the model. 
 
 
The paper is set out as follows. The paper begins by introducing concepts surrounding the role and 
interpretation of mathematical models in general, and attempts to highlight the importance of 
conceptual  modelling  within  the  broader  model  development  process.  Following  on  from  this, 
existing literature surrounding model structuring and conceptual modelling is briefly discussed. The 
paper then moves on to suggest a practicable framework for understanding the nature of the decision 
problem to be addressed in order to move towards a credible and acceptable final mathematical model 
structure. A series of potentially useful considerations is presented to inform this process. 
 
 
The interpretation of mathematical models 
 
A  mathematical  model  is  a  “representation  of  the  real  world…  characterised  by  the  use  of 
mathematics to represent the parts of the real world that are of interest and the relationships between 
those parts.”3 The roles of mathematical modelling are numerous, including extending results from a 
single  trial,  combining  multiple  sources  of  evidence,  translating  from  surrogate/intermediate 
endpoints to final outcomes, generalising results from one context to another, informing research 
planning and design, and characterising and representing decision uncertainty given existing 
information.
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At a broad level, mathematical or simulation models in Health Technology Assessment 
(HTA) are generally used to simulate the natural history of a disease and the impact of particular 
health technologies upon that natural history in order to estimate incremental costs, health outcomes 
and cost-effectiveness. 
 
 
All mathematical models require evidence to inform their parameters. Such evidence may include 
information   concerning   disease   natural   history   or   baseline   risk   of   certain   clinical   events, 
epidemiology, resource use and service utilisation, compliance/participation patterns, costs, health- 
related quality of life (HRQoL), survival and other time-to-event outcomes, relative treatment effects 
and relationships between intermediate and final endpoints. However, the role of evidence is not 
restricted to informing model parameters. Rather, it is closely intertwined with questions about which 
model parameters should be considered relevant in the first place and how these parameters should be 
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characterised. The consideration of how best to identify and use evidence to inform a particular model 
parameter thus firstly requires an explicit decision that the parameter in question is “relevant”, the 
specification or definition of that parameter, and some judgement concerning its relationship to other 
“relevant” parameters included in the model. This often complex and iterative activity is central to the 
process of model development and can be characterised as a series of decisions concerning (a) what 
should be included in the model, (b) what should be excluded, and (c) how those phenomena that are 
included should be conceptually and mathematically represented. 
 
 
The need for these types of decisions during model development is unavoidable, rather it is a 
fundamental characteristic of the process itself. Whilst this activity already takes place in health 
economic model development, it is often unclear how this process has been undertaken and how this 
may have influenced the final implemented model. In practice, the reporting of model structures tends 
to be very limited
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and, if present, usually focuses only on the final model that has been implemented. 
In such instances, the reader may be left with little idea about whether or why the selected model 
structure should be considered credible, which evidence has been used to inform its structure, why 
certain abstractions, simplifications and omissions have been made, why certain parameters were 
selected for inclusion (and why others have been excluded), and why the included parameters have 
been defined in a particular way. This lack of systematicity and transparency ultimately means that 
judgements concerning the credibility of the model in question may be difficult to make. In order to 
produce practically useful guidance concerning the use of evidence in models, it is firstly important to 
be clear about the interpretation of abstraction, bias and credibility in the model development process. 
 
 
i) Credibility of models 
 
A model cannot include every possible relevant phenomena; if it could it would no longer be a model 
but would instead be the real world. The value of simplification and abstraction within models is the 
ability to examine phenomena which are complex, unmanageable or otherwise unobservable in the 
real world. As a direct consequence of this need for simplification, all models will be, to some degree, 
wrong. The key question is not whether the model is “correct” but rather whether it can be considered 
to be useful for informing the decision problem at hand. This usefulness is directly dependent upon 
the credibility of the model’s results, which is, in turn, hinged upon the credibility of the model from 
which those results are drawn. Owing to the inevitability of simplification and abstraction within 
models, there is no single “perfect” or “optimal” model. There may however exist one or more 
“acceptable” models; even what is perceived to be the “best” model could always be subjected to 
some degree of incremental improvement (and indeed the nature of what constitutes an improvement 
requires some subjective judgement). The credibility of potentially acceptable models can be assessed 
and differing levels of confidence can be attributed to their results on the basis of such judgements. 
The  level  of  confidence  given  to  the  credibility  of  a  particular  model  may  be  determined 
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retrospectively – through considerations of structural and methodological uncertainty ex post facto, or 
prospectively – through the a priori consideration of the process through which decisions are made 
concerning the conceptualisation, structuring and implementation of the model. 
 
 
ii) Defining relevance in models 
 
The purpose of models is to represent reality, not to reproduce it. The process of model development 
involves efforts to reflect those parts of reality that are considered relevant to the decision problem. 
Judgements concerning relevance may differ between different modellers attempting to represent the 
same part of reality. The question of “what is relevant?” to a particular decision problem should not 
be judged solely by the individual developing the model; rather making such decisions should be 
considered as a joint task between modellers, decision-makers, health professionals and other 
stakeholders who impact upon or are impacted upon by the decision problem under consideration. 
Failure to reflect conflicting views between alternative stakeholders may lead to the development of 
models which represent a contextually naïve and uninformed basis for decision-making. 
 
 
iii) The role of clinical/expert input 
 
Clinical opinion is essential in understanding the relevant facets of the system in which the decision 
problem exists. This clinical opinion is not only relevant, but essential, because it is sourced from 
individuals who interact with this system in a way that a modeller cannot. This information forms the 
cornerstone of a model’s contextual relevance. However, it is important to recognise that health 
professionals cannot fully detach themselves from the system in which they practise; their views of a 
particular decision problem may be to some degree influenced by evidence they have consulted, their 
geographical location, local enthusiasms, their experience and expertise, together with a wealth of 
other factors. Understanding why the views of stakeholders differ from one another is important, 
especially with respect to highlighting geographical variations. As such, the use of clinical input in 
informing models and model structures brings with it the potential for bias. Bias may also be sourced 
from the modeller themselves as a result of their expertise, their previous knowledge of the system in 
which the current decision problem resides, and the time and resource available for model 
development. Where possible, potential biases should be brought to light to inform judgements about 
a model’s credibility. 
 
 
Problem-structuring in health economics and other fields 
 
It is important at this stage to note that whilst related to one another, there is a distinction between 
problem structuring methods (PSMs) and methods for structuring models. The former are concerned 
with understanding the nature and scope of the problem to be addressed, eliciting different 
stakeholders’ potentially conflicting views of the problem and developing consensus, exploring what 
potential options for improvement might be available, and even considering whether a problem exists 
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at all. There exist a number of methods to support this activity which have emerged from the field of 
“soft” Operational Research; these include Strategic Options Design and Analysis (SODA) and 
cognitive mapping, Soft Systems Methodology (SSM), Strategic Choice Approach and Drama Theory 
to name but a few. All stakeholders are seen as active “problem owners” and each of their views are 
considered important. The emphasis of PSMs is not to identify the “rationally optimal” solution, but 
rather to lay out the differing perceptions of the problem owners to foster discussion concerning 
potential options for improvement to the system. The value or adequacy of the PSMs is gauged 
according to whether they usefully prompt debate, with the intended endpoint being some agreement 
about the structure of the problem to be addressed and the identification and agreement of potential 
improvements to that problem situation. They do not necessarily assume that a mathematical model is 
appropriate or required. These methods are not discussed further here, but the interested reader is 
directed to the excellent introductory text by Rosenhead and Mingers.
6
 
 
 
Conversely,  formal  methods  for  model  structuring,  which  relates  principally  to  developing  a 
conceptual  basis  for  the  quantitative  model,  remain  comparatively  under-developed,  both  in  the 
context  of  health  economic  evaluation  as  well  as  in  other  fields.  A  recent  review  of  existing 
conceptual modelling literature
7 
concluded that whilst conceptual modelling is “probably the most 
important element of a simulation study”, there remains for the most part, a vacuum of research in 
terms of what conceptual modelling is, why it should be done, and how it may be most effectively 
implemented. Where formal conceptual modelling viewpoints have emerged, there is little consensus 
or consistency concerning how this activity should be approached. 
 
 
This problem is particularly applicable in the field of health economics. Recently, a qualitative 
research study was undertaken to examine techniques and procedures for the avoidance and 
identification of errors in HTA models.8 Interviewees included modellers working within Assessment 
Groups involved in supporting NICE’s Technology Appraisal Programme as well as those working 
for outcomes research groups involved in preparing submissions to NICE on behalf of pharmaceutical 
companies. A central aspect of these interviews involved the elicitation of a personal interpretation of 
how each interviewee develops models. These descriptions were synthesised to produce a stylised 
model development process, comprising five broad bundles of activities (see Box 1 and Figure 1). 
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Box 1:  Main stages in the model development process (adapted from Chilcott et al
8
) 
 
1. Understanding the decision problem: Activities including immersion in research evidence, 
defining the research question, engaging with clinicians, decision-makers and methodologists, and 
understanding what is feasible. 
2. Conceptual modelling: Activity related to translating the understanding of the decision problem 
towards a mathematical model-based solution.
7
 
3. Model implementation: Implementation of the model within a software platform. 
 
4. Model checking: Activity to avoid and identify model errors. This includes engaging with experts, 
checking face validity, testing values, structure and logic, checking data sources etc. 
5. Engaging with decision: Model reporting and use by the decision-maker(s). 
 
 
 
 
Figure 1: Stylised model development process
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One particular area of variability between interviewees concerned their approaches to conceptual 
model development. During the interviews, respondents discussed the use of several approaches to 
conceptual modelling including documenting proposed model structures, developing mock-up models 
in Microsoft Excel, developing sketches of potential structures, and producing written interpretations 
of evidence. For several respondents, the model development process did not involve any explicit 
conceptual modelling activity; in these instances, the conceptual model and implementation model 
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were developed in parallel with no discernable separation between the two activities. This is an 
important distinction to make with respect to model credibility and validation (as discussed below) 
and the processes through which evidence is identified and used to inform the final implemented 
model. 
 
 
Definition and purpose of conceptual modelling 
 
Whilst others have recognised the importance of conceptual modelling as a central element of the 
model development process, it has been noted that this aspect of model development is probably the 
most  difficult  to  undertake  and  least  well  understood.
7;9    
Part  of  the  problem  stems  from 
inconsistencies in the definition and the role(s) of conceptual modelling, and more general 
disagreements concerning how such activity should be used to support and inform implementation 
modelling. The definition and characteristics of conceptual modelling are dependent on the perceived 
purposes of the activity. For the purpose of this document, conceptual modelling is taken as: “the 
abstraction and representation of complex phenomena of interest in some readily expressible form, 
such that individual stakeholders’ understanding of the parts of the actual system, and the 
mathematical  representation  of  that  system,  may  be  shared,  questioned,  tested  and  ultimately 
agreed.” 
 
 
Whilst there is inevitable overlap associated with processes for understanding the decision problem to 
be addressed, conceptual modelling is distinguishable from these activities in that it is targeted at 
producing tangible outputs in the form of one or more conceptual models. In the context of health 
economic evaluation, conceptual model development may be used to achieve a number of ends, as 
highlighted in Box 2. Broadly speaking, these roles fall into two groups: (1) those associated with 
developing, sharing and testing one’s understanding of the decision problem and the system in which 
this exists, and (2) those associated with designing, specifying and justifying the model and its 
structure. Therefore it seems sensible to distinguish between problem-oriented conceptual models and 
design-oriented conceptual models; this distinction has been made elsewhere outside of the field of 
health economics.
10 
The characteristics of these alternative types of conceptual model are briefly 
detailed below. Both of these types of model may be useful approaches for informing the relevant 
characteristics of a health economic model. 
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Box 2:  The roles of conceptual modelling in health economic model development 
 
Problem-oriented conceptual models 
 
•  To ensure that health professionals understand how the model will capture the impact of the 
interventions under consideration on costs and health outcomes 
 
•  To ensure that the proposed model will be clinically relevant - that all relevant events, 
resources, costs and health outcomes have been included and that these reflect current 
knowledge of disease and treatment systems 
 
• To ensure that the proposed model will meet the needs of the decision-maker 
 
• To provide a reference point during model implementation 
 
• To highlight uncertainty and variation between healthcare practitioners 
 
Design-oriented conceptual models 
 
•  To  provide  a  common  understanding  amongst  those  involved  in  model  development 
regarding model evidence requirements prior to model implementation 
 
•  To provide an explicit platform for considering and debating alternative model structures and 
other model development decisions prior to implementation (including the a priori 
consideration of structural uncertainties) 
 
• To provide a reference point during model implementation 
 
•  To provide the conceptual basis for reporting the methods and assumptions employed within 
the final implemented model 
 
•  To provide a basis for comparison and justification of simplifications and abstractions during 
model development 
 
 
Problem-oriented conceptual models: This form of conceptual model is developed to understand 
the decision problem and the system in which that problem exists. The focus of this model form 
concerns fostering communication and understanding between those parties involved in informing, 
developing, and using the model. In health economic evaluation, this type of conceptual model is 
primarily concerned with developing and agreeing a description of the disease and treatment systems: 
(a) to describe the current clinical understanding of the relevant characteristics of the disease 
process(es)  under  consideration  and  important  events  therein,  and;  (b)  to  describe  the  clinical 
pathways through which patients with the disease(s) are detected, diagnosed, treated and followed-up. 
This type of conceptual model is therefore solely concerned with unearthing the complexity of the 
decision problem and the system in which it exists; its role is not to make assertions about how those 
relevant aspects of the system should be mathematically represented. The definition of “what is 
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relevant?” for this type of conceptual model is thus primarily dependent on expert input rather than 
the availability of empirical research evidence. In this sense, this type of conceptual model is a 
problem-led method of enquiry. 
 
 
Design-oriented conceptual models: This form of conceptual model is focussed on the consideration 
of alternative potentially acceptable and feasible quantitative model designs, to specify the model’s 
anticipated evidence requirements, and to provide a basis for comparison and justification against the 
final implemented model. In order to achieve these ends, it draws together the problem-oriented 
conceptual views of relevant disease and treatment processes and interactions between the two. The 
design-oriented conceptual model sets out a clear boundary around the model system, defines its 
breadth  (how  far  down  the  model  will  simulate  certain  pathways  for  particular  patients  and 
subgroups) and sets out the level of depth or detail within each part of the model. It therefore 
represents a platform for identifying and thinking through potentially feasible and credible model 
development choices prior to actual implementation. Within this context, the definition of “what is 
relevant?” is guided by the problem-oriented models and therefore remains problem-led, but is 
mediated by the question of “what is feasible?” given the availability of existing evidence and model 
development resources (available time, money, expertise etc.). 
 
 
Conceptual modelling activity, however defined, is directly related to model credibility and 
validation.
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The absence of an explicit conceptual model means that a specific point of model 
validation is lost. As a model cannot include everything, an implemented model is inevitably a subset 
of  the  system described by the  problem-oriented  conceptual  model. This  hierarchical separation 
allows simplifications and abstractions represented in the implemented model to be compared against 
its conceptual counterpart, thereby allowing for debate and justification.
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However, in order to make 
such comparisons, conceptual model development must be overt: the absence or incomplete 
specification of a conceptual model leads to the breakdown of concepts of model validation and 
verification.  Without  first  identifying  and  considering  the  alternative  choices  available,  it  is 
impossible to justify the appropriateness of any particular model. Further, without first setting out 
what is known about the relevant disease and treatment processes, the extent or impact of particular 
assumptions and simplifications cannot be drawn out explicitly. Therefore, the benefit of separating 
out conceptual modelling activity into distinct problem-oriented and design-oriented components is 
that this allows the modeller (and other stakeholders) to firstly understand the complexities of the 
system the model intends to represent, and then to examine the extent to which the simplifications and 
abstractions resulting from alternative “hard” model structures will deviate from this initial view of 
the system. Figure 2 shows the hierarchical relationship between the real world, the problem- and 
design-oriented conceptual models and the final implemented model. 
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Figure 2: A hierarchy of models 
 
 
 
 
Practical approaches to conceptual modelling in HTA 
 
This section suggests how conceptual modelling could be undertaken and which elements of model 
development activity should be reported. Practical considerations surrounding conceptual model 
development are detailed below with reference to a purposefully simple model to assess the cost- 
effectiveness of adjuvant treatments for a hypothetical cancer area. These considerations are intended 
to be broadly generaliseable to economic analysis within other diseases and conditions. It should be 
noted that the illustrative model is only intended to suggest how the alternative conceptual models 
forms  may  be  presented  and  used.  The  problem-oriented  model  is  divided  into  two  separate 
conceptual model views; a disease process model and a service pathways model. 
 
 
Problem-oriented conceptual modelling - disease process models 
 
Figure 3 presents a simple example of a conceptual disease process model for the hypothetical 
decision problem. The focus of this type of model is principally on relevant disease events and 
processes rather than on the treatments received. At each point in the pathway, the focus should 
therefore relate to an individual patient’s true underlying state rather than what is known by healthcare 
professionals at a particular point in time. It should be reiterated that this type of conceptual model 
does not impose or imply any particular decision concerning modelling methodology or appropriate 
outcome measures; it is solely a means of describing the relevant clinical events and processes within 
the system of interest. It should also be noted that such conceptual models should be accompanied by 
textual descriptions to support their interpretation and to capture any factors or complexities which are 
not represented diagrammatically. 
13  
Figure 3: Illustrative disease process model 
 
Tumour 
progresses 
 
Patient suffers Progression-free Post-progression Patient dies 
relapse 
 
Patient undergoes complete 
surgical excision of Patient is 
their primary tumour disease-free Death from other-causes or 
metastatic cancer 
 
 
Patient does not Patient is cured 
relapse 
 
 
Death from other causes 
 
The following non-exhaustive set of issues and considerations may be useful when developing and 
reporting this type of problem-oriented conceptual model: 
 
 
Inclusion/exclusion of disease-related events 
 
• What are the main relevant events from a clinical/patient perspective? Does the conceptual 
model include explicit reference to all clinically meaningful events? For example, could a 
patient experience local relapse? Or could the intervention affect other diseases (e.g. late 
secondary malignancy resulting from radiation therapy used to treat the primary tumour)? 
• Can these relevant events be discretised into a series of mutually exclusive biologically 
plausible health states? Does this make the process easier to explain? 
o If so, which metric would be clinically meaningful or most clinically appropriate? 
 
Which discrete states would be clinically meaningful? How do clinicians think about 
the disease process? How do patients progress between these states or sequences of 
events? 
o If not, how could the patient’s preclinical trajectory be defined? 
 
• Do  alternative  staging  classifications  exist,  and  if  so  can/should  they  be  presented 
simultaneously? 
• Are all relevant competing risks (e.g. relapse or death) considered? 
 
• For models of screening or diagnostic interventions, should the same metric used to describe 
preclinical and post-diagnostic disease states? 
• Is the breadth of the conceptual model complete? Does the model represent all relevant states 
or possible sequences of events over the relevant patient subgroups lifetime? 
• What are the causes of death? When can a patient die from these particular causes? Can 
patients be cured? If so, when might this happen and for which states does this apply? What is 
the prognosis for individuals who are cured? 
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Impact of the disease on HRQoL and other outcomes 
 
• Is there a relationship between states, events and HRQoL? Which events are expected to 
impact upon a patient’s HRQoL? 
• Does  the  description  of the  disease  process  capture  separate  states  in  which  a  patient’s 
 
HRQoL is likely to be different? 
 
• Does the description of the disease process capture different states for prognosis? 
 
Representation of different-risk subgroups 
 
• Is it clear which competing events are relevant for particular subgroups? 
 
• Does the description of the disease process represent a single patient group or should it 
discriminate between different subgroups of patients? 
• Are these states/events likely to differ by patient subgroup? 
 
Impact of the technology on the conceptualised disease process 
 
• Have all competing technologies relevant to the decision problem been identified? 
 
• Can the conceptual model be used to explain the impact(s) of the technology or technologies 
under assessment? Do all technologies under consideration impact upon the same set of 
outcomes in the same way? 
• Are there competing theories concerning the impact(s) of the technology upon the disease 
process? Can these be explained using the conceptual model? 
• Does the use of the health technology result in any other impacts upon health outcomes that 
cannot be explained using the conceptual disease process model? 
 
 
Problem-oriented conceptual modelling – service pathways models 
 
Figure 4 presents an illustrative service pathways model for the hypothetical decision problem. In 
contrast  to  the  disease  process  model,  the  focus  of  the  service  pathways  model  is  principally 
concerned with the health care interventions received based upon what is known or believed by 
healthcare practitioners at any given point in time. Again, such conceptual models should be 
accompanied by textual descriptions to ensure clarity in their interpretation and to retain any 
complexity which is not or cannot be captured diagrammatically. 
  
 
Figure 4: Illustrative service pathways model 
 
 
Patient dies during initial adjuvant chemotherapy period 
 
Patient survives surgery - returns to 
follow-up (same schedule but surgeon-led, 
potential complications) 
 
 
 
Patient dies during follow-up 
 
yes Peri-operative death 
Patient Adjuvant chemotherapy Follow-up test 1 (6 months) Eligible/fit for Metastasectomy Death 
survives 6 months  further curative 
surgery (Using regimen 1, 2 or 3) Findings surgery? 
normal no Palliative treatment 
(Spiritual support, symptom 
Follow-up test 2 (12 months) no relief) Patient dies 
 
- Drug acquisition Findings Patient fit for yes 
- Administration (OP) normal palliative 1st line palliative 
- Pharmacy preparation/ Relapse chemotherapy? chemotherapy 
dispensing Follow-up test 3 (24 months) detected 
- Drugs (to manage AEs) Intolerable adverse events 
- Line insertion Findings disease progression - Imaging 
normal - Drugs (to manage AEs) 
2nd line palliative - Potential hospitalisation 
Follow-up test 4 (48 months) chemotherapy - Clinical consultations 
- Administration (IP/OP) 
Intolerable adverse events - Drug acquisition costs (cycle-based) 
disease progression - Line insertion 
Discharge (cured) - Pharmacy preparation/dispensing 
salvage 
chemotherapy 
Relapse within 6 months 
 
 
IP – inpatient; OP - outpatient 
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The following issues and considerations may be useful when developing and reporting this type of 
conceptual model: 
 
 
Relationship between risk factors, prognosis and service pathways 
 
• Is it clear where and how patients enter the service? Is it clear where patients leave the service 
 
(either through discharge or death)? 
 
• Does the model make clear which patients follow particular routes through the service? 
 
• Are any service changes occurring upstream in the disease service which may influence the 
casemix of patients at the point of model entry? E.g. if surgical techniques were subject to 
quality improvement might this change patient prognosis further downstream in the pathway? 
• Does the model highlight the potential adverse events resulting from the use of particular 
interventions throughout the pathway? What are these? Do they apply to all competing 
technologies under consideration? 
• Are   there   any   potential   feedback   loops   within   the   system  (e.g.   resection→follow- 
 
up→relapse→re-resection→follow-up)? 
 
• Which  patients  receive  active  treatment  and which receive  supportive  care alone? What 
information is used to determine this clinical decision (e.g. fitness, patient choice)? 
Distinction between what is true and what is known 
 
• How does the pathway change upon detection of the relevant clinical events, as defined in the 
conceptual disease process model? For example, at what point may relapse be detected? 
• Is the occurrence of certain events likely to be subject to interval censoring? 
 
Geographical variations 
 
• How do the service pathways represented in the model likely to vary by geographical location 
or local enthusiasms? What are these differences and which parts of the pathway are likely to 
be affected most? 
Nature of resource use 
 
• What are the relevant resource components across the pathway and what is the nature of 
resource use at each point of intervention? E.g. routine follow-up dependent on relapse status, 
once-only surgery (except for certain relapsing patients), cycle-based chemotherapy, doses 
dependent on certain characteristics, dose-limited radiation treatment etc. 
• Does the conceptual service pathways model include all relevant resource components? 
 
• Which resources are expected to be the key drivers of costs? 
 
Impact of the technology on the service pathway 
 
• Which elements of the conceptual model will the intervention under assessment impact upon? 
 
E.g. different costs of adjuvant treatment, different mean time in follow-up, different numbers 
of patients experiencing metastatic relapse? What are expected to be the key drivers of costs? 
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Box 3 presents recommendations for developing and reporting problem-oriented conceptual models. 
 
 
 
Box 3:  Recommendations for practice – problem-oriented models 
 
(1)  Develop the structure of the problem-oriented conceptual model using clinical guidelines and 
health professionals 
(2)  Use other health professionals not involved in model development to provide peer review and 
to check understanding of the conceptual models 
(3)  The precise graphical approach for presenting the conceptual models is important only in that 
they should be easily understood by health professionals and other decision stakeholders 
(4)  For the sake of clarity, it may be beneficial to present the model in both diagrammatic and 
textual forms using non-technical, non-mathematical language 
(5) Develop the problem-oriented models before developing the design-oriented model. The 
feasibility and acceptability of the design-oriented conceptual model should have no bearing 
on the adequacy of the problem-oriented conceptual models. 
 
 
Practical considerations – design-oriented conceptual models 
 
Figure 5 presents an example of a design-oriented conceptual model for the hypothetical decision 
problem. Again, note that this is not intended to represent the “ideal” model but merely illustrates the 
general approach; there could be a number of design-oriented conceptual models that may be 
considered credible and acceptable by those parties using the model. This type of model draws 
together the problem-oriented model views with the intention of providing a platform for considering 
and agreeing structural model development decisions. By following this general conceptual approach 
it should be possible to identify the anticipated evidence requirements for the model at an early stage 
in model development. 
 
 
Anticipated evidence requirements to populate the proposed illustrative model are likely to include the 
following types of information: 
•  Time-to-event data to describe sojourn time/event rates and competing risks in States 1-4 for 
the current standard treatment 
•  Relative  effect  estimates for  the  intervention(s)  versus  comparator  (e.g.  hazard  ratios  or 
independent hazards time-to-event data) 
• Information relating to survival following cure 
 
• HRQoL utilities for cancer and cured states 
 
• Estimates of QALY losses or utility decrements and duration data for adverse events 
 
•  Information concerning the probability that a relapsed patient undergoes active/palliative 
treatment 
18  
• Survival and other time-to-event outcomes for relapsed patients 
 
• Resource use and costs associated with: 
 
o Chemotherapy  (drug  acquisition,  administration,  pharmacy/dispensing,  drugs  to 
manage adverse events, line insertion) 
o Resource use and unit costs for follow-up 
 
o Supportive care following relapse 
 
o Active treatments following relapse 
 
 
It  may be  helpful  to  consider  the  following  issues  when  developing  design-oriented  conceptual 
models. 
 
Anticipated evidence requirements 
 
• What clinical evidence is likely to be available through which to simulate the impact of the 
new intervention(s)? How should these parameters be defined and what alternatives are 
available? Should independent or proportional hazards be assumed? 
• Are all relevant interventions and comparators compared within the same trial? If not, is it 
possible for outcomes from multiple trials to be synthesised? How will this be done? 
• What evidence is required to characterise adverse events within the model? What choices are 
available? 
• Beyond the baseline and comparative effectiveness data relating to the technology itself, what 
other outcomes data will be required to populate the downstream portions of the model (e.g. 
progression-free survival and overall survival by treatment type for relapsed patients, survival 
duration in cured patients)? 
• Will any intermediate-final relationships be modelled? What external evidence is there to 
support such relationships? What are the uncertainties associated with this approach and how 
might these be reflected in the model? 
• Which  descriptions  of  HRQoL  states  are  possible  and  how  will  these  parameters  be 
incorporated into the final model? 
• Will all model parameters be directly informed by evidence or will calibration methods (e.g. 
 
Markov Chain Monte Carlo) be required? Which calibration methods will be used and why 
should these be considered optimal or appropriate? 
• What pre-model analysis will be required to populate the model? Which parameters are likely 
to require this? 
  
State 5 
 
 
Figure 5: Illustrative design-oriented conceptual model 
 
 
TTE 1 
 
 
TTE 2 TTE 3 
 
 
 
State 1 (Model entry point) State 2 State 4 State 5 (Model exit point) 
Alive, relapse-free, on chemo  Alive, relapse-free, in follow-up  Alive, post-relapse, active or Dead 
(max 6months sojourn)  (up to 48 months)  supportive care 
 
Chemo & associated costs  Follow-up tests/appointment costs  Proportion active/palliative tx (P1) Absorbing state 
(dependent on sojourn time and TTE 4 (dependent on sojourn time and TTE 5 Costs active tx and supportive care    TTE 6 No cost of death 
compliance)   compliance)   dependent on P1 and TTE5 in 
AE costs subgroup 
 
HRQoL1 (age-independent)  HRQoL1 (age-independent)  HRQoL2 for active tx subgroup 
QALY loss for AEs QALY loss for AEs due to active tx 
HRQoL3 for supportive care 
subgroup 
 
TTE 7 
 
 
State 3 
Cured 
 
No further health system costs 
 
TTE 8 
 
 
HRQoL1 (return to healthy population 
status) 
 
 
 
 
TTE = time to event; AE = adverse event 
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Modelling clinical outcomes 
 
• Which outcomes are needed by the decision-maker and how will they be estimated by the 
model? 
• How/should trial evidence be extrapolated over time? 
 
• If final outcomes are not reported within the trials, what evidence is available concerning the 
relationship between intermediate and final outcomes? How might this information be used to 
inform the analysis of available evidence? 
• How will the impact(s) of treatment be simulated? How will this directly/indirectly influence 
costs and health outcomes? What alternative choices are available? 
Modelling approach 
 
• Which methodological approach (e.g. state transition, patient-level simulation) is likely to be 
most appropriate? Why? 
• Is   the   proposed   modelling   approach   feasible   given   available   resources   for   model 
development? 
• How does the approach influence the way in which certain parameters are defined? What 
alternatives are available (e.g. time-to-event rates or probabilities)? 
• Does the proposed modelling approach influence the level of depth possible within certain 
parts of the model? 
Adherence to a health economic reference case 
 
• Will the proposed model meet the criteria of the reference case specific to the decision- 
making jurisdiction in which the model will be used? If not, why should the anticipated 
deviations be considered appropriate? 
Simplifications and abstractions 
 
• Have any relevant events, costs or outcomes been purposefully omitted from the proposed 
model structure? Why? For what reason(s) may these omissions be considered appropriate? 
• Are there any parts of the disease or treatment pathways that have been excluded altogether? 
 
Why? 
 
• What is the expected impact of such exclusion/simplification decisions? Why? 
 
• What are the key structural simplifications? How does the design-oriented model structure 
differ from the problem-oriented conceptual models? Why should these deviations be 
considered appropriate or necessary? What is the expected direction and impact of these 
exclusions on the model results? 
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Box 4:  Recommendations for practice – design-oriented conceptual models 
 
 
• The design-oriented conceptual model should be developed initially prior to the development 
of the final implementation model. It may, however, be revisited and modified within an 
iterative process during the development of the quantitative model. 
• Model development involves making a large number of decisions and judgements. Not every 
decision or judgement made during model development will be important. The key decisions 
are likely to be those whereby the implemented model clearly deviates from the problem- 
oriented models (e.g. a part of the system is excluded) or whereby several alternative choices 
exist but none of which are clearly superior (i.e. structural uncertainties). These decisions 
should be clearly documented and reported. 
• The sources of evidence used to inform model structure and the methods through which this 
information is elicited should be clearly reported. 
• Where possible, alternative model development choices drawn out at this stage should be later 
tested using the quantitative model to assess their impact upon the model results. This will not 
however always be possible or feasible. 
 
 
Evidence sources to inform conceptual models 
 
A number of potential evidence sources may be useful for informing these types of conceptual model. 
Whilst the evidence requirements for any model will inevitably be broader than that for traditional 
systematic reviews of clinical effectiveness, the task of obtaining such evidence should remain a 
systematic,  reproducible  process  of  enquiry.  Possible  sources  of  evidence  to  inform  conceptual 
models include: (1) clinical input; (2) existing systematic reviews; (3) clinical guidelines; (4) existing 
efficacy studies; (5) existing economic evaluations or models, and; (6) routine monitoring sources. 
Table 1 sets out some pragmatic concerns which should be borne in mind when using these evidence 
sources to inform conceptual model development. 
  
 
Table 1: Roles and concerns regarding the use of evidence to inform alternative model structures 
 
Existing economic evaluations / models Expert input (including clinicians and 
potentially patients/service users) 
Clinical guidelines / previous 
TA guidance / local treatment 
protocols 
Empirical clinical studies and reviews 
(e.g. RCTs, cohort studies) 
Principal role(s) in conceptual model development 
•  To apply previously developed model 
structure to the current decision problem 
under consideration 
•  To use existing economic analyses to 
highlight key evidence limitations 
•  To identify possible options for model 
development decisions 
•  To identify relevant treatment pathways 
•  To inform problem-oriented conceptual 
model development 
•  To scrutinise the credibility of alternative 
model structures 
•  To elucidate uncertainty regarding 
geographical variation 
•  To identify existing 
treatment/management 
pathways 
•  To highlight gaps in the 
existing evidence base 
•  To identify available evidence to 
inform relationships between 
intermediate and final endpoints 
•  To investigate what evidence is 
available 
Issues and caveats associated with use 
•  Existing models should not be relied upon 
without considerable scrutiny. 
•  Publication or other forms of dissemination 
of an existing model does not guarantee 
that the previous model was either 
appropriate or credible. 
•  Advances in knowledge may render an 
existing model redundant 
•  There may exist a gap between the 
decision problem that the model was 
developed to address and the current 
decision-problem under consideration 
•  Seek input from more than one health 
professional to capture the spectrum of 
clinical opinion 
•  Use multiple experts located in different 
geographical locations 
•  There exists a trade-off between seeking 
support from individuals with 
considerable expertise and standing (may 
not have much time but more 
experience/knowledge) and less 
experienced clinicians (may have more 
time to engage but lesser knowledge of 
evidence base). 
•  Health professionals cannot be 
completely objectively detached from the 
system the model intends to represent 
•  May be difficult to distinguish between 
conflict and geographical variations 
•  Potential conflicts of interest 
•  Potential ethical restrictions 
•  Current practice may have 
evolved since publication of 
guidance 
•  Such evidence sources may 
not provide sufficient detail 
to inform the current 
decision problem 
•  Local protocols may not 
reflect geographical 
variations between centres 
•  Local protocols and 
guidelines may not be 
evidence-based 
•  There may exist a gap 
between what should happen 
and what does in happen in 
clinical practice 
•  Potential reliance on the availability of 
evidence rather than the structure of 
the problem 
•  Differences between studies may 
suggest competing theories regarding 
(a) the nature of the disease process 
and (b) the relevance of particular 
events. This is not a problem as such 
but should be drawn out during 
conceptual model development. 
•  Treatments and comparators may 
reflect historical rather than current or 
best practice 
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Discussion 
 
This paper has set out a view of the model development process as one which is centred 
around the concept of uncertainty and choice. This process may be best characterised as a 
series of decisions concerning (a) what should be included in the model, (b) what should be 
excluded, and (c) how those phenomena that are included should be conceptually and 
mathematically represented. The unavoidable need to make such decisions has important 
implications  for  the  interpretation  of  models,  as  none  will  be  perfect,  but  several  may 
credible, acceptable or adequate. However, in order for these judgements of credibility to be 
made, the underlying conceptual basis of models must be made clear. Only through the 
explicit use of conceptual models can deviations and simplifications be assessed, debated and 
agreed. The paper then moves on to propose a generalised approach for the development and 
reporting of conceptual models, with particular emphasis placed on the difference between 
problem-oriented and design-oriented models. These conceptual model forms are interrelated 
but  serve  different  purposes  during  model  development.  The  paper  concludes  with  a 
discussion of the potential roles of alternative sources of evidence in informing conceptual 
model development. 
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